18-07-2018
miodrag ignjatovic / iStockphoto.com
US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Humira, Mylan, licence agreement, patent, patent agreement, Amgen, generics, biopharmaceuticals
Mylan fails to void MSD diabetes treatment patent at PTAB
11-05-2021
US Tax Court says Mylan can deduct patent litigation fees
29-04-2021
AbbVie and Momenta announce Humira patent licence agreement
08-11-2018
AbbVie enters Humira licensing deal with Fresenius Kabi
22-10-2018
AbbVie secures another Humira settlement
12-10-2018
AbbVie escalates Humira battle with Sandoz
13-08-2018
AbbVie and Alphabet company commit $1bn to collaboration
27-06-2018
AbbVie and Amgen settle Humira clash
29-09-2017
